Becton, Dickinson and Company (BD) reported a revenue increase of 5.2% for the second quarter of fiscal year 2026, totaling $4.714 billion, compared to $4.480 billion in the same period last year. The growth was attributed to a 2.4% increase in volume, a 0.2% rise in pricing, and a 2.6% positive impact from foreign currency fluctuations. However, the company experienced a net loss of $311 million for the quarter, a significant decline from a net income of $308 million in the prior year, primarily due to losses from discontinued operations related to the spin-off of its former Biosciences and Diagnostic Solutions business.
In terms of operational changes, BD completed the spin-off of its Biosciences and Diagnostic Solutions business on February 9, 2026, in a Reverse Morris Trust transaction with Waters Corporation. This strategic move resulted in a cash distribution of $4 billion to BD, which was utilized for share repurchases and debt repayments. The company repurchased approximately $2.250 billion of its common stock during the first half of fiscal 2026, reflecting its commitment to returning value to shareholders.
BD's organizational structure was also redefined, eliminating the Life Sciences segment and reorganizing into four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, and BD Interventional. This restructuring aims to enhance operational efficiency and align resources with the company's strategic priorities. The company reported a total employee headcount of 75,000 as of March 31, 2026, a slight decrease from the previous year, reflecting ongoing efforts to streamline operations.
Geographically, BD's U.S. revenues grew by 5.1% to $2.917 billion, driven by strong performance in its Medical Essentials and Connected Care segments. International revenues also increased by 5.5%, although challenges in the Chinese market, particularly related to volume-based procurement programs, impacted overall growth. Emerging markets showed an 8.3% revenue increase, indicating BD's continued focus on expanding its presence in these regions.
Looking ahead, BD anticipates ongoing challenges from macroeconomic factors, including inflation and supply chain disruptions, which may affect future performance. The company remains committed to investing in research and development, geographic expansion, and new product initiatives to drive growth. BD's management emphasized the importance of operational excellence and innovation as key components of its strategy moving forward.
About BECTON DICKINSON & CO
Becton, Dickinson and Company (BD) is a global medical technology firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. Its three main segments—BD Medical, BD Life Sciences, and BD Interventional—serve healthcare institutions, physicians, researchers, and pharmaceutical companies worldwide. BD focuses on improving medication management, patient safety, infection prevention, diagnostics, and surgical care through innovative, quality-driven solutions distributed via direct and independent channels.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.